Baxter reports another strong quarter
This article was originally published in Scrip
Executive Summary
Stronger than expected second-quarter revenues, in particular for biologicals and vaccines, sawBaxter's share price rise to an all-time high of $69.66 on Thursday July 17th, and to close at $67.96, up by 3.2%.